The public perception of the human papillomavirus (HPV) is that it is a “women’s virus”, primarily associated with cervical cancer. In vaccination campaigns, prevention plans and sex education in schools, HPV mainly appears in a gynecological context. However, HPV is a ubiquitous, sexually transmitted infection with proven oncogenic potency – not only in the cervix, but also in numerous urological tissues. Particularly in a discipline such as uro-oncology, where the molecular approach to tumor biology is becoming increasingly important, the question arises: How relevant is HPV really for urological carcinomas?
You May Also Like
- Chronic pain
Nano-ECS modulator Adezunap improves therapy success
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Important basics and studies on cancer and the psyche